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Background: High-intensity ultrasound pulses intermittently triggered from an ECG signal can interact with
circulating contrast agent microbubbles to produce myocardial cavitation microlesions of potential therapeutic
value. In this study, the timing of therapy pulses relative to the ECG R wave was investigated to identify the optimal
time point for tissue reduction therapy with regard to both the physiological cardiac response and microlesion
production.
Methods: Rats were anesthetized, prepared for ultrasound, placed in a heated water bath, and treated with
1.5 MHz focused ultrasound pulses targeted to the left ventricular myocardium with an 8 MHz imaging transducer.
Initially, the rats were treated for 1 min at each of six different time points in the ECG while monitoring blood
pressure responses to assess cardiac functional effects. Next, groups of rats were treated at three different time
points: end diastole, end systole, and mid-diastole to assess the impact of timing on microlesion creation. These rats
were pretreated with Evans blue injections and were allowed to recover for 1 day until hearts were harvested for
scoring of injured cardiomyocytes.
Results: The initial results showed a wide range of cardiac premature complexes in the ECG, which corresponded
with blood pressure pulses for ultrasound pulses triggered during diastole. However, the microlesion experiment
did not reveal any statistically significant variations in cardiomyocyte injury.
Conclusion: The end of systole (R + RR/3) was identified as an optimal trigger time point which produced
identifiable ECG complexes and substantial cardiomyocyte injury but minimal cardiac functional disruption during
treatment.
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Hypertrophic cardiomyopathyBackground
Myocardial contrast echocardiography provides the cap-
ability of perfusion imaging with ultrasound [1,2]. Con-
trast agents, which consist of suspensions of stabilized
microbubbles, are injected intravenously and increase the
echogenicity of the myocardium. When relatively high
pressure-amplitude ultrasound pulses are used, for ex-
ample, greater than about 1 MPa at 2 MHz [3], the micro-
bubbles are destroyed, clearing the contrast enhancement
and revealing the relative microbubble content by com-
paring the before and after images. If the process is* Correspondence: douglm@umich.edu
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unless otherwise stated.repeated with different intervals between the clearance
pulses, then the relative perfusion of different regions is
discernable. In addition to the diagnostic application, this
imaging method can be enhanced for therapeutic pur-
poses. The strong, cavitation-like response of the micro-
bubbles at relatively high peak rarefactional pressure
amplitudes (PRPAs) can lead to a variety of microscale
bioeffects in contrast-enhanced diagnostic ultrasound
[4]. The local bioeffects, or microlesions, are attributable
to nucleation of inertial cavitation [5,6]. The bioeffects
have the potential to be harnessed in several therapeutic
strategies [7].
Myocardial contrast echocardiography has been shown
to be capable of causing lethal injury of cardiomyocytes,
which leads to scattered microlesions throughout thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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one or a few lethally injured cardiomyocytes, heal within
a few weeks with minimal scarring [9]. Recently, this
phenomenon was proposed as a means of ultrasound
therapy in which the scattered microlesions would in-
nocuously heal, leaving a measured reduction in tissue
volume [10]. This noninvasive and relatively gentle
method of tissue reduction might be advantageous, for
example, in treatment of hypertrophic cardiomyopathy
(HCM) and other ventricular hypertrophies. Echocardi-
ography is the optimum method for diagnosis of these
conditions, and extension of the imaging methods to
therapeutic application may be particularly advanta-
geous clinically. The treatment would be repeatable and
avoid methods with relatively high impact and patient
risk such as alcohol ablation [11,12] or surgical myectomy
[12,13]. Parameters for myocardial cavitation-enabled ther-
apy (MCET) were optimized for microlesion production
using 1.5-MHz-focused ultrasound pulses, which were
trigged at mid-cardiac cycle and guided by 8-MHz diag-
nostic ultrasound [10]. Evans blue-stained cardiomyo-
cyte scores (SCSs) were used to assess the relative
efficacy with 2 or 4 MPa pulses, 1:4 or 1:8 trigger inter-
vals, and 5 or 10 cycle pulses. The results indicated a
major increase in efficacy by increasing the PRPA from
2 MPa, in the diagnostic range, to 4 MPa, which often
exceeded the microlesioning level needed for therapeutic
tissue reduction. The increased intervals and pulse dura-
tions did not yield significant increases in the effects.
These findings suggested that MCET can potentially be-
come a clinically robust therapeutic tool after refinement
and control of the treatment process.
The purpose of this study was to examine the impact
of this method on cardiac function during treatment and
to determine the best time point in the ECG for applica-
tion of the therapeutic pulses. We hypothesized that
ultrasound-induced arrhythmia, blood pressure perturb-
ation, and microlesion production would have significant
dependences on the timing of the therapy pulses within
the heart cycle. In addition, for treatment in many pa-
tients, significant perturbation of cardiac function might
pose significant risks and become an important consider-
ation for treatment planning. An optimum combination
of minimal cardiac functional disruption and treatment ef-
ficacy is needed for this therapy method. The lethal injury
of cardiomyocytes is accompanied by premature com-
plexes (PCs) in the ECG [14], but the meaning of these
complexes was not fully understood. In order to establish
whether or not these signals announce actual premature
ventricular contractions, or possibly only pulseless elec-
trical activity, the heart function was investigated using
real-time blood pressure monitoring for a 4-MPa treat-
ment at six different time points in the cardiac cycle. In
addition, to determine if cardiomyocyte microlesionformation is dependent on cardiac cycle and presumed
myocardial blood vessel volume (systole = reduced blood
volume; diastole = increased volume), treatment efficacy
evaluated by microlesion formation was compared with
pulses delivered at end diastole, end systole, or mid-
diastole. The results provided key information for treat-
ment planning with regard to the response of the heart
during treatment and the therapeutic outcome.
Materials and methods
Animal preparation
All in vivo animal procedures were conducted with the ap-
proval and guidance of the University Committee on Use
and Care of Animals. Twenty-eight male Sprague-Dawley
rats (Charles River, Wilmington, MA, USA) weighing
331 ± 33 g were tested for this study. One rat was used
for preliminary setup and one did not survive for the
1-day examination. Rats are the most common mamma-
lian animal model for cardiovascular research, particu-
larly for studies requiring numerous animals and test
groups [15]. Rat models for hypertrophic cardiomyopathy
are available [16], but often difficult to obtain. However,
even Sprague-Dawley rats have a tendency toward left
ventricular hypertrophy [17] and therefore seem to be a
good model for this study.
Rats were anesthetized by intraperitoneal (IP) injection of
a mixture of ketamine (90 mg/kg) and xylazine (9 mg/kg),
and the left thorax was shaved and depilated for ultrasound
transmission. A 24-gauge cannula was inserted into a tail
vein for IV injections of contrast agent. In seven rats, a
catheter with a pressure sensor (model SPR-320 2 F
catheter, Millar Instruments, Houston, TX, USA) was
inserted into a femoral artery and the sensor advanced
to the abdominal aorta. The blood pressure signal was
amplified with a bridge amplifier and calibrated using a
calibration kit (FE221 and MLA1052, ADInstuments,
Inc., Colorado Springs, Co, USA). In 21 rats, Evans blue
dye in saline (20 mg/ml) was injected IV at a dose of
100 mg/kg as a vital stain for cardiomyocytes [8]. ECG
electrodes were applied and the rats were positioned in
a warmed water bath for ultrasound scanning and treat-
ment. The ECG and blood pressure signals were digitized
(Powerlab 4/30, ADInstruments Inc., Colorado Springs,
CO, USA), recorded, and analyzed with the aid of software
(Chart Pro 5, v. 5.5.5, ADInstruments Inc., Colorado
Springs, CO, USA).
Ultrasound
Ultrasound exposure was provided by a laboratory sys-
tem with guidance by diagnostic ultrasound imaging.
The 1.9-cm-diameter therapy transducer with a 3.8-cm
focus was mounted on a moveable gantry together with
the 8-MHz diagnostic probe used at 8 MHz, 5-cm depth,
and low −14-dB power setting (mechanical index 0.2).
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for low-power imaging of the heart during exposure.
The aim was adjusted to focus the beam into the win-
dow between ribs and between the sternum and lung
and to enter the heart approximately at the middle of
the left ventricle. The exposure consisted of bursts of
eight pulses triggered from the ECG signal using optimal
parameters of five cycle pulses with 4-MPa PRPA, deter-
mined previously [10]. For this study, the pulse amplitudes
were re-measured in the water bath using a calibrated
hydrophone (Model 805, Sonora Medical systems Inc.,
Longmont, Co, USA). The pulses were triggered 1:4 at a
desired time point relative to the heart cycle determined
by the ECG signal.
The ECG signal and the blood pressure signal, when
monitored, were recorded for 1 min before treatment,
during treatment, and for 1 min after treatment. The
ECG signal provides a crude monitor of the treatment
because premature complexes in the ECG at the trigger
points are strongly correlated with lethal cardiomyocyte
injury. For rats with overnight recovery, the ECG also
was recorded for 1 min prior to euthanasia. Definity®
(Lantheus Medical Imaging, Inc., North Billerica, MA,
USA) ultrasound contrast agent was infused at 5 μl/kg/
min, diluted 100:1 in sterile saline. After placement and
stabilization of a rat in the water bath for a few minutes,
the R wave-to-R wave (RR) interval was measured and the
desired trigger point set. For exposure, the probes were
set, the Definity infusion was initiated, and the therapy ex-
posure was started at the appearance of the contrast agent
in the left ventricle.
Cardiomyocyte scoring
The development of microlesions was assessed in sam-
ples obtained 1 day after treatment. The microlesions
were scored on the basis of Evans blue staining [10].
Each heart was evaluated from up to 40 frozen sections
cut at 200-μm spacing, and the scores were totaled in an
effort to characterize the overall impact. For these ther-
apy experiments, the large accumulations of stained cells
in frozen sections were often difficult to accurately count
and the resulting scores remained qualitative (rather
than an actual cell count). As an additional measure of
the overall cardiomyocyte injury, plasma samples were
collected after 1 day and analyzed for troponin I with an
ELISA assay kit (Rat Cardiac Tn-I (Ultra Sensitive), Life
Diagnostics Inc., West Chester, PA, USA). This cardiac
enzyme is a sensitive indicator of cardiac injury in ro-
dents [18] and provides an indicator of the total amount
of cell killing.
Experimental plan
The study was conducted in two parts. The first part
tested six rats using varying trigger timing with bloodpressure monitoring. The RR interval of each rat was de-
termined, and the trigger time point was stepped by in-
crements of RR/6 for six 1-min treatments. In order to
average any trend with time for the six treatments, the
sequence was started at a different time point for each
rat. Specifically, the first through sixth rat was started at
the R wave (R + 0RR/6), the R wave plus a delay of RR/6
(R + RR/6), R + 2RR/6, R + 3RR/6, R + 4RR/6, and R +
5RR/6, respectively. Rats in part 1 had the ECG and blood
pressure signals evaluated and samples of the treated area
of the heart taken for histology approximately 15 min after
the conclusion of treatments. The second part of the study
involved 20 rats in four groups treated as shams or treated
with pulse triggering at end diastole (R wave), at end sys-
tole (R + 2RR/6), or at mid-diastole (R + 4RR/6). These
rats had Evans blue injection and evaluation of the micro-
lesion production in hearts sampled the next day.
Results are reported as the means plus or minus one
standard deviation or plotted with standard error bars.
The data were evaluated by statistical analysis software
(SigmaPlot for Windows v. 11.0, Systat Software Inc., San
Jose, CA, USA). Student’s t-tests were used to compare
means of the measured parameters, with statistical signifi-
cance assumed at P < 0.05. In addition, repeated-measures
ANOVA analysis was used to examine the significance




In part 1, the six rats had an average RR interval of 230 ±
25 ms (263 ± 29 bpm), and the blood pressure was 121 ±
14-mm-Hg systolic and 81 ± 11-mm-Hg diastolic, with no
significant changes in these average measures during or
after treatment. The ECG and blood pressure traces for
one rat are shown in Figure 1. For this rat, the first expos-
ure minute was triggered at R + RR/6 and the last at R +
0RR/6. The PCs and blood pressure trace show a progres-
sion of changes as the trigger point was changed from the
R wave to the incrementally later times. The blood pres-
sure trace showed that end of systole, which is marked by
the brief deflection in slope caused by the closing of the
aortic valve [19], occurred at approximately R + 2RR/6.
Triggering at the R wave (end diastole) produced no dis-
cernable change in the signals. Triggering at R + 1RR/6
(early systole) or R + 2RR/6 (end systole) often yielded a
PC in the ECG and a prolonged decrease in blood pres-
sure during the compensatory pause before the next R
wave. However, triggering during diastole at R + 3RR/6 or
R + 4RR/6, which gave a PC in the ECG, elicited a pre-
mature pulse in the blood pressure signal. Triggering at
R + 5RR/6 (late diastole) essentially stimulated the next
heart beat to occur slightly earlier, often including the
P-wave in the PC.
Figure 1 Comparison plots of the ECG and blood pressure signals for one rat in part 1. The timing of the triggers for the high-intensity
therapy pulses was incremented by RR/6 and is shown by the vertical dotted lines. The treatment pulses typically elicited a premature complex in
the ECG, except for triggering at the R wave (R + 0RR/6). The blood pressure signal shows the heart functional response, with premature blood
pulses generated for R + 3RR/6 and later trigger points.
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sulted in PCs are shown in Figure 2. This percentage
was significantly greater (repeated-measures ANOVA)
than the very low value for triggering at the R wave (2 PCs
in one rat, or 0.4% ± 1.0%) for all the other trigger points.
The %PCs for R + 2RR/6, R + 3RR/6, and R + 4RR/6 werealso all greater than that for R + 1RR/6 (P < 0.001). The
blood pressure nadir at end of the compensatory pause
(delayed end of diastole) also varied with trigger points,
and the difference (pressure decline) between the pressure
at the end of diastole before and after a PC at different
trigger points is shown in Figure 3. These results were
Figure 2 A plot of the percentage of the triggered pulsed-
ultrasound exposures, which elicited premature complexes in
the ECG. At the R wave, any electrical activity, which might have
been generated by the exposure, was masked by the normal
complex of the ECG, and all the other results were statistically
significantly greater (asterisks) than at this time point.
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cycles for each rat at each trigger point. The decline was
as large as 13.2 ± 6.0 mm Hg for triggering at R + 2RR/6,
and declines for both R + 2RR/6 and R + 3RR/6 triggering
were significantly greater than that for triggering at the R
wave (repeated-measures ANOVA, P < 0.005). One rat in
the R + 1RR/6 group had PCs but no compensatory pause,
which gave approximately zero blood pressure decrease
for that rat, and one rat had no data due to a lack of PCs.
The hearts from part 1, which were removed soon after
treatment and did not contain Evans blue, showed a red
lesion spot corresponding to the ultrasound focal zoneFigure 3 A plot of the decreases in the end-diastolic blood
pressure caused by the compensatory pauses. The pauses
followed premature complexes induced by the triggered pulsed-
ultrasound exposures for the different trigger time points. The
decreases for both R + 2RR/6 and R + 3RR/6 triggering were
significantly greater (asterisks) than that for triggering at the R wave.entry (Figure 4a). This lesion was the result of numerous
capillary hemorrhages within the tissue as shown histolog-
ically in Figure 4b.
Part 2 results
In part 2, the relative response was determined for trig-
gering at the R wave, R + 2RR/6, or R + 4RR/6. The mean
RR interval for rats in part 2 was 217 ± 13 ms (278 ±
17 bpm) to start and 247 ± 78 ms (255 ± 48 bpm) the next
day. During treatment, the occurrence of PCs was signifi-
cant (P < 0.001) for triggering at R + 2RR/6 or R + 4RR/6,
as shown in Figure 5. A heart treated in part 2 with the
R + 2RR/6 trigger point, which was subjected to overnight
Evans blue staining and removed the next day, is shown in
Figure 4c. The lesion area visible on the surface is similar
to that shown in Figure 4a, except that the hemorrhage
marking is reduced and the central region is distinctly
blue. The blue region was primarily due to the presence of
stained cardiomyocytes, which were scored in frozen sec-
tions under fluorescence microcopy. A fluorescence image
of a frozen section at the approximate middle of the focal
damage zone for this heart is shown in Figure 4d. The
blue-stained cardiomyocytes in scattered microlesions ap-
pear fluorescent red, while the normal heart tissue appears
darker with only background fluorescence in this 3-color
image. The stained cell scores are compared in Figure 6.
The scores for the treated rats were all significantlyFigure 4 Photomicrographs of the effects of the treatment on
the heart. The beam entry for this heart from part 1 of the study is
evidenced by a red marking (a, scale bar 2 mm), which was due to
numerous capillary hemorrhages within the myocardium (b, scale
bar 0.5 mm). For a heart from part 2, a similar mark appears on the
heart except for blue staining of injured cardiomyocytes (c, scale bar
2 mm), which are shown in a frozen section by red fluorescence
(d, scale bar 2 mm).
Figure 5 The percentage of treatment pulse triggers resulting
in premature complexes in the ECG for part 2 of the study. The
triggers at R + 2RR/6 and R + 4RR/6 produced significantly (asterisks)
more premature complexes than triggering at the R wave or for
sham exposure.
Figure 7 The measurements of troponin I in plasma samples
taken a day after treatment. The results for all three trigger points
were about the same and significantly greater (asterisks) than the
very low scores in shams.
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not significantly different from each other. The troponin
results are compared in Figure 7. The results for the
treated rats were significantly different from shams (P <
0.05), but there was no significant difference between the
treated groups. These results for stained cell scoring and
troponin both indicate that the different trigger time
points produce about the same treatment impact.
Discussion
The timing of the therapy pulses relative to the R wave
can be readily varied for MCET. In this study, the influ-
ence of the trigger time point was investigated with re-
gard to both the physiological cardiac response and the
microlesion production. In the first part of the study,Figure 6 The scores from frozen sections for cardiomyocytes
stained by Evans blue. The scores for all three trigger points were
about the same and significantly greater (asterisks) than the very low
scores in shams.rats were treated for 1 min at each of six different time
points in the ECG with blood pressure monitoring dur-
ing treatment. This experiment revealed large differences
in the functional response of the heart in terms of the
ECG and blood pressure signals for different trigger time
points. To evaluate the impact of the ultrasound treatment
on cardiomyocyte injury, three different time points were
investigated: the R wave (end diastole), R wave plus one
third of the R-to-R interval (2RR/6, end systole), and R
wave plus 4RR/6 (mid-diastole). The results showed no sig-
nificant differences in the stained cell scores or plasma
troponin measurements for these three trigger time points.
The ECG signal showed many premature complexes
for trigger points other than at the R wave, see Figure 2.
The blood pressure trace helped to identify key timing
reference points, such as the closing of the aortic valve
at end of systole, which occurred at about R + 2RR/6.
The time points correspond to events in the heart cycle,
which is shown in a Wiggers diagram [19]. For triggers
at the R wave, there was essentially no perturbation in
heart function shown by the ECG or blood pressure sig-
nals. For R + 1RR/6 and R + 2RR/6, PCs were observed
but no blood pressure pulse was generated, because the
heart was already in contraction with the aortic valve
open. However, the blood pressure signal revealed pre-
mature pulses generated after PCs for triggering during
diastole at R + 3RR/6, R + 4RR/6, and R + 5RR/6, as shown
in Figure 1. These blood pulses must have required the
mitral valve to re-close and the aortic valve to re-open.
The compensatory pauses resulted in significant decreases
in diastolic blood pressure of up to 15% at the end of
diastole (Figure 3). The trigger timing at R + 5RR/6 pro-
duced minimal disturbance of the heart cycle but must
have interacted with the atrial contraction occurring
with the P-wave.
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of systole (R + 2RR/6). This setting yields clearly identifi-
able PCs, which are an indicator of microlesion produc-
tion [14] and provide real-time feedback on treatment
efficacy. The hypothesis that treatments occurring at
end systole might be less effective, because of decreased
myocardial vessel blood volume, was not supported (see
Figures 6 and 7). Although this timing results in a pro-
longed compensatory pause, which reduces end-diastolic
blood pressure for that cycle and may be felt by patients
who are awake, the PCs appear to be pulseless electrical
signals. If the trigger timing is set in diastole, then a
pulse is generated by premature ventricular contractions
and stressful valve actuation might occur. This finding
further refines MCET procedures, which also may be ap-
plicable to other cardiac therapy methods, such as drug,
gene, or stem cell delivery. Further research for develop-
ment of better microlesion scoring is in progress [20]. In
addition, improved real-time monitoring to control and
define the actual tissue reduction created will be needed
for safe and effective therapeutic application.
Conclusion
MCET allows the opportunity to adjust the timing of
therapy pulse-bursts within the cardiac cycle. The end of
systole (R + RR/3) was identified as an optimal trigger
time point which produced identifiable ECG complexes
and substantial cardiomyocyte injury but minimal car-
diac functional disruption during treatment.
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